AUTHOR=Chen Ming , Gao Yue , Gan Kai , Liu Kuangzheng , Xu Bin 

TITLE=SP1 Expression and the Clinicopathological Features of Tumors: A Meta-Analysis and Bioinformatics Analysis

JOURNAL=Pathology and Oncology Research

VOLUME=Volume 27 - 2021

YEAR=2021

URL=https://www.por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2021.581998

DOI=10.3389/pore.2021.581998

ISSN=1532-2807

ABSTRACT=Objective Specificity protein 1 (SP1) is an oncogene to promote carcinogenesis in a variety of tumors, and its up-regulated expression contributes to a poor prognosis of patients. We conducted this meta-analysis to elucidate the clinical significance and prognostic value of SP1 in malignant tumors.
Methods PubMed and Cochrane Library were searched for studies published between January 1, 2000 and June 1, 2020. The combined odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to investigate the correlation of SP1 with clinical behaviors and prognosis in patients with solid tumors. UALCAN was used to conduct bioinformatics analysis.
Results A total of 24 documents involving 2739 patients were enrolled in our review. The random-effect model was used to perform this analysis due to the high level of heterogeneity. SP1 low expression was not conducive to lymph node metastasis (OR=0.42; 95%CI:0.28-0.64; p<0.05), progression of TNM stage (OR=0.34;95%CI:0.20-0.57; p<0.05) and tumor infiltration (OR=0.33;95%CI:0.18-0.60; p<0.05). Elevated SP1 expression was connected with short survival time of patients (HR=1.95; 95%CI:1.16-3.28; p<0.05). According to UALCAN database, carcinoma tissues display an elevated SP1 expression in comparison with normal tissues and Kaplan-Meier survival plots indicate SP1 mRNA level has negative effects on prognosis.
Conclusion SP1 was associated with progression and prognosis in tumors, which brought new insights on the potential candidacy of SP1 in clinical usage.